GLP-3 RT (Retatrutide)

GLP-3 RT is VANTA’s designation for the triple GIP/GLP-1/glucagon receptor agonist studied in the scientific literature as retatrutide (research code LY3437943) — the most advanced incretin-based design currently in metabolic research.

What makes it distinct
Where GLP-1 mono-agonists engage one incretin receptor and dual agonists engage two (GIP + GLP-1), GLP-3 RT adds a third target: the glucagon receptor. This triple-receptor design is the focus of current research interest, studied in models for its effects on energy expenditure and hepatic lipid metabolism alongside the incretin pathways shared with earlier compounds.

Research context
GLP-3 RT is an investigational compound. The published data comes from controlled clinical studies of the pharmaceutical (Phase 2 in the New England Journal of Medicine, 2023; ongoing Phase 3 work), cited in the references below. This research-grade material is supplied for in-vitro and laboratory study only. For a full mechanism-and-literature overview, see our [GLP-3 RT / Retatrutide Research Overview »] and compare it with the dual-agonist [Tirzepatide »].

Purity & testing
– ≥99% purity (this lot: 99.85% by HPLC)
– Lyophilized powder for laboratory reconstitution
– Batch-specific Certificate of Analysis — HPLC + mass spec, heavy metals, sterility, endotoxin
– ISO/IEC 17025-accredited third-party testing → [View the COA »]

Laboratory handling
Store lyophilized material cold and protected from light (long-term at −20 °C). After reconstitution, refrigerate at 2–8 °C and use within your protocol window. Confirm identity and purity against the batch COA before use.

For laboratory and research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use. GLP-3 RT is an investigational, patent-protected molecule with no approved supply; these statements have not been evaluated by the FDA.